Shares of Medicure Inc. (CVE:MPH – Get Free Report) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$1.21 and traded as high as C$1.31. Medicure shares last traded at C$1.30, with a volume of 2,600 shares trading hands.
Medicure Stock Performance
The stock’s fifty day moving average is C$1.22 and its two-hundred day moving average is C$1.15. The firm has a market cap of C$19.83 million, a price-to-earnings ratio of -2.64 and a beta of 0.44. The company has a debt-to-equity ratio of 6.02, a quick ratio of 1.28 and a current ratio of 0.97.
About Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Featured Articles
- Five stocks we like better than Medicure
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
